(Q37995522)

26 August 2017

title

Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different? (English)

1 reference

26 August 2017

1 reference

Diane Reidy-Lagunes

1

1 reference

26 August 2017

Raymond Thornton

series ordinal

2

1 reference

26 August 2017

publication date

1 June 2012

1 reference

26 August 2017

published in

Current Oncology Reports

1 reference

26 August 2017

volume

14

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

249-256

1 reference

Everolimus for advanced pancreatic neuroendocrine tumors.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Prognostic factors in gastrointestinal endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Update on the management of neuroendocrine hepatic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Hepatic neuroendocrine metastases: does intervention alter outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

The management of patients with advanced carcinoid tumors and islet cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Activity of sunitinib in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0232-1

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

21 January 2018

1 reference

12 December 2020

Classification of low-grade neuroendocrine tumors of midgut and unknown origin

1 reference

12 December 2020

Gastrointestinal neuroendocrine tumors

1 reference

12 December 2020

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

12 December 2020

Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor

1 reference

12 December 2020

Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival

1 reference

12 December 2020

Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases

1 reference

12 December 2020

Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors

1 reference

12 December 2020

In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial

1 reference

12 December 2020

Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases

1 reference

12 December 2020

Neuroendocrine hepatic metastases: does aggressive management improve survival?

1 reference

12 December 2020

Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome

1 reference

12 December 2020

Expression of vascular endothelial growth factor in digestive neuroendocrine tumours

1 reference

12 December 2020

Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma

1 reference

12 December 2020

10.1007/S11912-012-0232-1

Identifiers

DOI

1 reference

26 August 2017

1 reference